Cited by 895Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsPancreatitis Pathology and Treatment

The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.

Molecular subtypes of pancreatic cancer

Open access

Collisson, Eric A., Bailey, Peter, Chang, David K., Biankin, Andrew V.·2019·Nature Reviews Gastroenterology & Hepatology

DOI 10.1038/s41575-019-0109-y

Open this paper in CoChat — free account

Abstract

Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease.

Integrity signals

Registry

Crossref · 10.1038/s41575-019-0109-y

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Cancer Statistics, 2017.
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citation
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Self-citation

Show all 119 references

Research works printed but not linked: 1

Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 2140–2141 (2014).

Sorted by citations

Items 501–600 of 895

Genomic determinants of biological aggressiveness and poor prognosis of pancreatic cancers: KRAS and beyond
Ciulla, C., & Luchini, C. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2348676 · Cited by 5
Circulating necroptosis markers in chronic pancreatitis and pancreatic cancer: Associations with diagnosis and prognostic factors
Belfrage, H., Kuuliala, K., Kuuliala, A., Mustonen, H. K., Puolakkainen, P. A., Kylänpää, L., Seppänen, H. E., & Louhimo, J. M. (2024) · Pancreatology · doi:10.1016/j.pan.2024.11.016 · Cited by 5
FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects
Wang, W., Liu, X., Zhao, L., Jiang, K., Yu, Z., Yang, R., Zhou, W., Cui, J., & Liang, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1505027 · Cited by 5
Selective Autophagy Conceals the Enemy: Why Cytotoxic T Cells Don’t (MH)C Pancreatic Cancer
Božić, M., & Wilkinson, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.009 · Cited by 5
New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting
Heßmann, E., Schneider, G., Bousquet, C., Der, C. J., Dreyer, S. B., Dusetti, N., Eilers, M., Ellenrieder, V., Espinet, E., Falcomatà, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.082 · Cited by 5
Molecular Profiling in Pancreatic Cancer: Current Role and Its Impact on Primary Surgery
Reyes, C. M., Doğruöz, A., Istvánffy, R., Frieß, H., Ceyhan, G. O., & Demir, İ. E. (2021) · Visceral Medicine · doi:10.1159/000519755 · Cited by 5
A Comparative Study of Patient-Derived Tumor Models of Pancreatic Ductal Adenocarcinoma Involving Orthotopic Implantation
Yanagihara, K., Iino, Y., Yokozaki, H., Kubo, T., Oda, T., Kubo, T., Komatsu, M., Sasaki, H., Ichikawa, H., Kuwata, T., et al. (2022) · Pathobiology · doi:10.1159/000521714 · Cited by 5
High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma
Callahan, S. C., Kochat, V., Liu, Z., Raman, A. T., Divenko, M., Schulz, J., Terranova, C. J., Ghosh, A. K., Tang, M., Johnson, F. M., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.936168 · Cited by 5
Cellular heterogeneity in pancreatic cancer: the different faces of gremlin action
Moustakas, A., Löhr, M. J., & Heuchel, R. L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01203-8 · Cited by 5
Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage
Wang, K., Hua, X.-D., Fu, X.-B., Hao, Z.-Q., Jiao, A., & Li, S.-Y. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4494 · Cited by 2
IGF2BP2-related modification patterns in pancreatic cancer: A machine learning-driven approach towards personalized treatment
Chen, D., Zang, L., Zhou, Y., Yang, Y., Zhang, X., Li, Z., Shu, Y., Gao, W., Zhu, H., & Yu, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28243 · Cited by 5
Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic
Mattiolo, P., Kryklyva, V., Brosens, L. A. A., Mafficini, A., Lawlor, R. T., Milella, M., Scarpa, A., Corbo, V., & Luchini, C. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2021397 · Cited by 5
Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse modelPreprint
English, I. A., Worth, P. J., Hawthorne, K., Vergara, M., Pelz, K. R., Kiemen, A. L., Shah, V., Blise, K. E., Pelz, C., Tsuda, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.14.664767 · Cited by 6
Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma: Aligning Guideline Recommendations with Real-World Evidence
Cammarata, R., Catamerò, A., Vaccara, V. L., Coppola, R., & Caputo, D. D. (2025) · Cancers · doi:10.3390/cancers17183085 · Cited by 4
Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
Wang, X., Wang, H., Zhang, M., Li, H., Liu, Y., Huang, H., Pei, J., Huang, J., Zang, F., Zhang, Y., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0323 · Cited by 4
Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma
Boudreault, J., Rahimirad, S., Wang, N., Yan, G., Lima, L. C., Poulet, S., Dai, M., Ali, S., & Lebrun, J. J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02587-9 · Cited by 5
Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma
Schmitt, A. M., Gätje, F. B., Tran, M. Y. R., Midelashvili, T., Xu, X., Fleischer, J. R., Spahn, H., Lai, K., Tacke, T., Younes, S., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02628-3 · Cited by 4
Single-cell spatial transcriptional profiling of pancreatic ductal adenocarcinoma uncovers key immune-modulating and pro-metastatic mechanisms
Zhou, J., Shi, G., Dai, S., Wu, S., Qian, F., Wu, Z., Zhang, J., Yang, Y., Xiao, B., Lu, Z., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218613 · Cited by 4
Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer
Chen, G., Liu, Y., Su, D., Qiu, J., Long, J., Zhao, F., Tao, J., Yang, G., Huang, H., Xiao, J., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00836-3 · Cited by 4
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors
Davis, S. L., Messersmith, W. A., Purcell, W. T., Lam, E. T., Corr, B. R., Leal, A. D., Lieu, C. H., O’Bryant, C. L., Smoots, S. G., Dus, E. D., et al. (2024) · Cancers · doi:10.3390/cancers16081456 · Cited by 4
Identifying drug candidates for pancreatic ductal adenocarcinoma based on integrative multiomics analysis
Ge, P., Wang, Z., Wang, W., Gao, Z., Li, D., Guo, H., Qiao, S., Dang, X., Yang, H., & Wu, Y. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-985 · Cited by 4
The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival
van Eijck, C. W. F., Ju, J., Land, F. R. V. ‘., Verheij, M., Li, Y., Stubbs, A., Doukas, M., Lila, K. A., Heij, L. R., Wiltberger, G. J., et al. (2024) · Pancreatology · doi:10.1016/j.pan.2024.08.014 · Cited by 4
Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity
Jung, O., Soto, A., Wolfe, A. L., & Mahajan, S. S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329946 · Cited by 4
Albumin‐Mediated Delivery of Bioactive Peptides for Pancreatic Cancer Therapy
Du, Y., Shang, B.-Y., Yi, H., Yuan, Y., Zhen, Y., & Xu, J. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000003 · Cited by 4
A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma
Chen, Y., Lin, X., Zou, X., Qian, Y., Liu, Y., Wang, R., Wang, X., Yu, X., Liu, C., & Cheng, H. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02748-w · Cited by 4
hTERT Gene Modification Using CRISPR-dCas9-dnmt3a System as a Therapeutic Approach Against Glioma
Rad, F. T., Ghorbian, ‪., Gargari, B. N., Shirvani-Farsani, Z., & Sharifi, R. (2023) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-137226 · Cited by 4
WNT enhancing signals in pancreatic cancer are transmitted by LGR6
Wang, J., Koch, D. T., Hofmann, F. O., Härtwig, D., Beirith, I., Janssen, K., Bazhin, A. V., Nieß, H., Werner, J., Renz, B. W., et al. (2023) · Aging · doi:10.18632/aging.205101 · Cited by 5
Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction
Ziogas, D. C., Papadopoulou, E., Gogas, H. J., Sakellariou, S., Felekouras, E., Theocharopoulos, C., Stefanou, D. T., Theochari, M., Boukovinas, I., Matthaios, D., et al. (2023) · Cancers · doi:10.3390/cancers16010002 · Cited by 4
KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry‐based subtyping
Rao, J., Sinn, M., Pelzer, U., Riess, H. B., Oettle, H., Demir, İ. E., Friess, H., Jäger, C., Steiger, K., & Muckenhuber, A. (2024) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.12377 · Cited by 4
A Probabilistic Approach to Estimate the Temporal Order of Pathway Mutations Accounting for Intra-Tumor Heterogeneity
Wang, M., Xie, Y., Liu, J., Li, A., Chen, L., Stromberg, A. J., Arnold, S. M., Liu, C., & Wang, C. (2024) · Cancers · doi:10.3390/cancers16132488 · Cited by 4
Patient subtyping analysis of baseline multi-omic data reveals distinct pre-immune states associated with antibody response to seasonal influenza vaccination
Bayrak, Ç. S., Forst, C. V., Jones, D. R., Gresham, D., Pushalkar, S., Wu, S., Vogel, C., Mahal, L. K., Ghedin, E., Ross, T. M., et al. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110333 · Cited by 4
Treating chronic atrophic gastritis: identifying sub-population based on real-world TCM electronic medical records
Wang, Y.-M., Sun, J., Sun, R.-X., Liu, X., Li, J. Y., Li, R., Du, Y.-R., & Zhou, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1444733 · Cited by 4
Progress of Exosomal LncRNAs in Pancreatic Cancer
Wei, C., Zhang, C., Zhou, Y., Wang, J., & Jin, Y. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168665 · Cited by 4
Advancing targeted therapies in pancreatic cancer: Leveraging molecular abberrations for therapeutic success
Gupta, T., & Murtaza, M. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.02.003 · Cited by 6
Neoadjuvante und adjuvante Therapie beim Pankreaskarzinom
Springfeld, C., Hackert, T., Jäger, D., Büchler, M. W., & Neoptolemos, J. P. (2020) · Der Chirurg · doi:10.1007/s00104-020-01169-9 · Cited by 4
Cytology-based Detection of Circulating Tumour Cells in Human Pancreatic Cancer Xenograft Models WithKRASMutation
Ιtο, Y., INOUE, E., Matsui, Y., Kobuchi, S., Moyama, C., Amagase, K., Yoshimura, M., Ikehara, Y., Nakata, S., & Nakanishi, H. (2020) · Anticancer Research · doi:10.21873/anticanres.14701 · Cited by 4
Down‐regulation of metabolic pathways could offset the poor prognosis conferred by co‐existent diabetes mellitus in pancreatic (head) adenocarcinoma
Gardi, N., Ketkar, M., McKinnon, R. A., Pandol, S. J., Dutt, S., & Barreto, S. G. (2021) · ANZ Journal of Surgery · doi:10.1111/ans.17194 · Cited by 4
Therapeutic effects of an innovative BS-HH-002 drug on pancreatic cancer cells via induction of complete MCL-1 degradation
Wang, A.-M., Qiu, R., Zhang, D., & Zhao, X. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101288 · Cited by 4
Establishment of a 4-miRNA Prognostic Model for Risk Stratification of Patients With Pancreatic Adenocarcinoma
Gong, X., Liu, Y., Zheng, C., Tian, P., Peng, M., Pan, Y., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.827259 · Cited by 4
Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating With the Response to Immunotherapy in Patients With Gastric Cancer
Wang, G., Yang, L., Wang, Y., Hu, R.-H., Zhang, K., Guo, T., Chen, B., Jiang, X., & Cui, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.939836 · Cited by 4
Modeling Obesity-Driven Pancreatic Carcinogenesis—A Review of Current In Vivo and In Vitro Models of Obesity and Pancreatic Carcinogenesis
Kfoury, S., Michl, P., & Roth, L. (2022) · Cells · doi:10.3390/cells11193170 · Cited by 5
The novel subclusters based on cancer-associated fibroblast for pancreatic adenocarcinoma
Zhao, G., Wang, C., Jiao, J., Zhang, W., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1045477 · Cited by 4
Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data
WANG, X., JIANG, S., ZHOU, X., Wang, X., Li, L., & Tang, J. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.029458 · Cited by 4
Endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling
Okuno, N., & Hara, K. (2024) · Journal of Medical Ultrasonics · doi:10.1007/s10396-023-01403-x · Cited by 4
Association of Mutant KRAS Alleles With Morphology and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
Chao, T., Wang, Z., Bowne, W. B., Yudkoff, C. J., Torjani, A., Swaminathan, V., Kavanagh, T. R., Roadarmel, A., Sholevar, C. J., Cannaday, S., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0005-oa · Cited by 4
Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes
Karpiński, P., Łaczmański, Ł., & Sasiadek, M. M. (2020) · Journal of Immunology Research · doi:10.1155/2020/8758090 · Cited by 4
Disease subtyping using community detection from consensus networks
Nguyen, H., Tran, B., Tran, D., Nguyen, Q., Le, D., & Nguyen, T. (2020) · International Conference on Knowledge and Systems Engineering/Proceedings · doi:10.1109/kse50997.2020.9287843 · Cited by 4
Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network
Qu, Y., Lu, J., Mei, W., Jia, Y., Bian, C., Ding, Y., Guo, Y., Cao, F., & Li, F. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-709 · Cited by 4
SPDEF promotes the classical subtype of pancreatic ductal adenocarcinomaPreprint
Tonelli, C., Yordanov, G. N., Yuan, H., Deschênes, A., Klingbeil, O., Ting, H.-C., Brosnan, E., Doshi, A., Park, Y., Vakoc, C. R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.18.484951 · Cited by 4
A novel DNA repair protein, N-Myc downstream regulated gene 1 (NDRG1), links stromal tumour microenvironment to chemoresistancePreprint
Kozlova, N. V., Cruz, K. A., Doh, H. M., Ruzette, A. A., Willis, N. A., Hong, S. M., González, R. S., Vyas, M., Selfors, L. M., Dreyer, S. B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.22.634323 · Cited by 4
Self-citation
Integrated Transcriptome Analysis Reveals Molecular Subtypes and ceRNA Networks in Multiple Sclerosis
Ji, C., Ding, L., Jia, F., Zhang, Z., & Long, C. (2024) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s491211 · Cited by 3
Identification of progression related LncRNAs in colorectal cancer aggressiveness
Wei, X., Sun, X., Wang, M., Wang, X., Li, K., Jiang, R., Jia, X., & Wang, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-02096-7 · Cited by 4
Molecular Imaging: Unveiling Metabolic Abnormalities in Pancreatic Cancer
Wang, H., Gui, Y., & Lv, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115242 · Cited by 3
Hypoxia promotes pancreatic adenocarcinoma progression by stabilizing ID1 via TRIM21 suppression
Cheng, R., Tang, Y., Cao, X., Huang, Z., Guo, Y., Jin, R., Wang, Y., Liu, Y., Xue, L., & Wang, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1616968 · Cited by 3
Evolution of the Spatial transcriptomic landscape during the progression of high-grade pancreatic intraductal papillary mucinous neoplasms to invasive cancer
Peng, S., Chen, Q., Chen, Z., Yao, M., Cai, Y., He, D., Cai, Y., Cheng, K., Li, J., Cai, H., et al. (2025) · Pancreatology · doi:10.1016/j.pan.2025.12.012 · Cited by 3
Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models
Tanji, Y., Shimada, S., Kato, M., Akiyama, Y., Hatano, M., Tsukihara, S., Igarashi, Y., Kodera, K., Okazaki, K., Yasukawa, K., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106137 · Cited by 3
FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
Lamarca, Á., Foster, L., Valle, J. W., Satyadas, T., & Siriwardena, A. K. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000633 · Cited by 3
A probabilistic model for pathway-guided gene set selection
Kim, I., Lee, S., Kim, Y., Namkoong, H., & Kim, S. (2021) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm52615.2021.9669350 · Cited by 3
The utility of molecular studies on pancreatic cystic lesions: A comprehensive review
Xia, R., Liu, X., Hajdu, C. H., Cao, W., Kaz, J. N., Gonda, T. A., & Simsir, A. (2024) · Human Pathology Reports · doi:10.1016/j.hpr.2024.300741 · Cited by 3
Tumor-derived exosome PPP3CB induce gemcitabine resistance by regulating miR-298/STAT3 in pancreatic cancer
Wang, C., Xu, S., & Qin, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36434 · Cited by 3
Intratumor heterogeneity in KRAS signaling shapes treatment resistance
Petrenko, O., Kirillov, V., D’Amico, S., & Reich, N. C. (2024) · iScience · doi:10.1016/j.isci.2024.111662 · Cited by 3
Improved Predictability of Diagnosis and Prognosis Using Serum‐ and Tissue‐Derived Extracellular Vesicles From Bulk mRNA Sequencing in Pancreatic Ductal Adenocarcinoma
Zhu, Q., Chen, Z., Tian, M., Yan, X., Gongye, X., Liu, Z., Zhao, A., Yang, Z., & Yuan, Y. (2025) · Cancer Medicine · doi:10.1002/cam4.70538 · Cited by 3
The Biology in the Pattern: Metastatic Organotropism and Clinical Outcome Depend on DNA Damage Response and Immune Interactions in Pancreatic Cancer
Papargyriou, A., & Reichert, M. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1085 · Cited by 3
Transmission electron microscopic analysis of pancreatic ductal adenocarcinoma cell spheres formed in 3D cultures
Shichi, Y., Fujiwara, M., Gomi, F., Nonaka, K., Hasegawa, F., Shinji, S., Rokutan, H., Arai, T., Takahashi, K., & Ishiwata, T. (2025) · Medical Molecular Morphology · doi:10.1007/s00795-025-00435-1 · Cited by 3
Qingyihuaji formula reprograms metabolism to suppress pancreatic cancer growth and progression through LINC00346-OMA1-ATF4 signaling
Shi, W., Wang, Z., Yu, Z., Shen, Y., Xin, W., & Chen, W. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119893 · Cited by 3
Identification of the "Collagen-Macrophage" sub-category of patients with colorectal cancer as an extension of the CMS4 subtype with THBS2 as a therapeutic target
Chen, S., Jiang, Z., Song, W., Lu, C., Lin, Y., Xu, S. S., Xie, K., Wan, L., & Yuan, X. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03918-8 · Cited by 3
Genome-scale activation screen reveals lncRNA HNF1A-AS1 promotes pancreatic cancer metastasis through interacting with U2SURP to increase CD44 alternative splicing
Lei, S., Zhang, Z., Zeng, Z., Cao, W., Sun, Y., Li, D., Pan, J., Wu, Y., Zhang, T., & Chen, T. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02272-6 · Cited by 3
Unveiling the mechanisms and promising molecular targets of curcumin in pancreatic cancer through multi-dimensional data
Xie, H., Liang, J., He, H., Zhuo, Z., & Li, J.-X. (2025) · Scientific Reports · doi:10.1038/s41598-025-05346-w · Cited by 3
The value of nucleoporin 188 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to gastric cancer verification
Zhu, Z., Peng, R., & Cai, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1586784 · Cited by 3
The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma
Mao, Y., Cheng, W., Yang, Q., Li, L., Hu, W., Shuang, Z., Fan, D., Jiang, X., Gao, F., Li, S., et al. (2021) · Genomics · doi:10.1016/j.ygeno.2021.11.036 · Cited by 3
Artificial Intelligence-based Multiomics Integration Model for Cancer Subtyping
Bhat, A. R., & Hashmy, R. (2022) · International Conference on Computing for Sustainable Global Development · doi:10.23919/indiacom54597.2022.9763283 · Cited by 3
Replication stress identifies novel molecular classification associated with treatment outcomes in pancreatic cancer
Zhou, Z., Saluja, A. K., Houchen, C. W., & Li, M. (2022) · Pancreatology · doi:10.1016/j.pan.2022.11.008 · Cited by 3
Construction of a radiogenomic association map of pancreatic ductal adenocarcinoma
Jamshidi, N., Senthilvelan, J., Dawson, D. W., Donahue, T. R., & Kuo, M. (2023) · BMC Cancer · doi:10.1186/s12885-023-10658-z · Cited by 3
Learning Individual Survival Models from PanCancer Whole Transcriptome Data
Kumar, N., Skubleny, D., Parkes, M., Verma, R., Davis, S., Kumar, L., Aissiou, A., & Greiner, R. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3493 · Cited by 3
Elevated serum MMP-1 associated with advanced disease stage and lymph node metastasis in patients with pancreatic carcinoma.
Xu, X., Ji, H., Guo, Z., & Lu, X. (2023) · PubMed Central · Cited by 3
miR-1180 Targets FXYD5 to Regulate Pancreatic Cancer Cells Migration and Invasion
Xie, H., Li, J., Lu, M., Zhang, R., & Mao, H. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00923-8 · Cited by 3
Analytical Validation of Loss of Heterozygosity and Mutation Detection in Pancreatic Fine-Needle Aspirates by Capillary Electrophoresis and Sanger Sequencing
Timmaraju, V. A., Finkelstein, S. D., & Levine, J. A. (2024) · Diagnostics · doi:10.3390/diagnostics14050514 · Cited by 3
Single-cell transcriptome reveals the heterogeneity of malignant ductal cells and the prognostic value of REG4 and SPINK1 in primary pancreatic ductal adenocarcinoma
Ji, Y., Xu, Q., & Wang, W. (2024) · PeerJ · doi:10.7717/peerj.17350 · Cited by 3
PDAC heterogeneity resolved spatially at the single‐cell level: new biological answers, new questions on optimal translation†
Felipe‐Abrio, I., & Real, F. X. (2024) · The Journal of Pathology · doi:10.1002/path.6293 · Cited by 3
Validation of a targeted next-generation sequencing panel for pancreatic ductal adenocarcinomas
Racu, M.-L., Schiavo, A. A., Campenhout, C. V., Nève, N. D., Masuy, T., Maris, C., Decaestecker, C., Remmelink, M., Salmon, I. J., & D’Haene, N. (2024) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2024.104920 · Cited by 3
New Onset Diabetes in Pancreatic Adenocarcinoma Does Not Correlate With Molecular Subtype
Trembath, H. E., LaBella, M. E., Kearney, J. F., Hariharan, A., Zarmer, S., Nabors, M., McCabe, I. C., Zhao, R. T., Meyers, M. O., Kim, H. J., et al. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.28044 · Cited by 3
Tumor subtype classification tool for HPV-associated head and neck cancers
Li, S., Garb, B. F., Qin, T., Soppe, S., Lopez, E. F., Patil, S. B., D’Silva, N. J., Rozek, L. S., & Sartor, M. A. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107726 · Cited by 3
Environment Influences Tumor Progression and Transcriptional Subtype in a New Model of Pancreatic Cancer
Pickering, K. A., & Morton, J. P. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1090 · Cited by 3
Split Cyclin-Dependent Kinase 4/6–Retinoblastoma 1 Axis in Pancreatic Cancer
Huang, X., & Zhang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.602352 · Cited by 3
Mandatory Reporting Measurements in Trials for Potentially Resectable Pancreatic Cancer
Pijnappel, E. N., Suurmeijer, J. A., Koerkamp, B. G., Siveke, J. T., Salvia, R., Ghaneh, P., Besselink, M. G., Wilmink, J. W., & van Laarhoven, H. W. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_8 · Cited by 3
Immunotherapeutic Approach for Advanced Pancreatic Adenocarcinoma
Kaur, J., Mir, T., Gill, R., Duong, J., Marcus, S., & Khan, R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0344 · Cited by 4
Das duktale Adenokarzinom des Pankreas: Subtypen und Molekularpathologie
Schlitter, A. M., Konukiewitz, B., Kasajima, A., Reichert, M., & Klöppel, G. (2021) · Der Pathologe · doi:10.1007/s00292-021-00965-2 · Cited by 3
Metastasis Suppressor Genes in Pancreatic Cancer
Bhattacharya, A., Santhoshkumar, A., Kurahara, H., & Harihar, S. (2021) · Pancreas · doi:10.1097/mpa.0000000000001853 · Cited by 3
Transcription factors as drivers of distinct pancreatic ductal adenocarcinoma (PDAC) programmes: a role for HNF4A
Diaferia, G. R., & Natoli, G. (2020) · Gut · doi:10.1136/gutjnl-2020-322814 · Cited by 3
BaBao Dan Suppresses Tumor Growth of Pancreatic Cancer Through Modulating Transcriptional Reprogramming of Cancer-Related Genes
Song, L., Fang, Z., Pan, C., Chen, X., Xiang, Q., Cai, Y., Zhang, X., & Liu, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584330 · Cited by 3
Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King
Attiyeh, M. A., Amini, A., Chung, V. M., & Melstrom, L. G. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26415 · Cited by 3
Pancreatic Cancer and the Family Connection: The Role of Advanced Practitioners in Screening and Educating Genetically At-Risk Individuals
Lowe, T. B., DeLuca, J. M., Abenavoli, L., & Boccuto, L. (2023) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2023.14.6.6 · Cited by 14
Flatsomatic: A Method for Compression of Somatic Mutation Profiles in CancerPreprint
Dubourg-Felonneau, G., Kussad, Y., Kirkham, D., Cassidy, J. W., Patel, N., & Clifford, H. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1911.13259 · Cited by 3
The integration of Tgfβ and Egfr signaling programs confers the ability to lead heterogeneous collective invasionPreprint
Nasir, A., Camacho, S., McIntosh, A. T., Graham, G. T., Rahhal, R., Huysman, M. E., Alsharief, F., Riegel, A. T., & Pearson, G. W. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.14.383232 · Cited by 2
Cytidine deaminase protects pancreatic cancer cells from replicative stress and drives resistance to DNA-targeting drugsPreprint
Lumeau, A., Béry, N., Francès, A., Gayral, M., Ribeyre, C., Lopez, C., Nevot, A., Elkaoutari, S., Labrousse, G., Madrid-Mencía, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.23.465566 · Cited by 3
An examination of pre-entry and academic performance factors that predict persistence for academically underprepared students at a public research university
Stewart, S. (2010) · ProQuest Demo Repository · Cited by 3
Targeting keratin 17-mediated reprogramming of de novo pyrimidine biosynthesis to overcome chemoresistance in pancreatic cancerPreprint
Pan, C., Chaika, N. V., Tseng, R., Siraj, M. A., Chen, B., Donnelly, K. L., Horowitz, M., Leiton, C. V., Chowdhury, S., Roa‐Peña, L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.24.504873 · Cited by 3
Neoplasms of the Exocrine Pancreas
Wolff, R. A., Li, D., Maitra, A., Tsai, S., Koay, E. J., & Evans, D. B. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm094.pub2 · Cited by 3
Compressed phenotypic screens for complex multicellular models and high-content assaysPreprint
Mead, B. E., Kummerlowe, C., Liu, N., Kattan, W. E., Cheng, T., Cheah, J. H., Soule, C. K., Peters, J., Lowder, K. E., Blainey, P. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.23.525189 · Cited by 3
Heparin Prowess: Favorable Vascular–Immune Reprogramming in Pancreatic Cancer
Korc, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0346 · Cited by 3

Authors: Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V.
Affiliations: University of California, San Francisco (US)
University of Glasgow (GB)
Glasgow Royal Infirmary (GB)
Corresponding author: Biankin, Andrew V.
ORCID: Collisson, Eric A.
Bailey, Peter
Chang, David K.
Biankin, Andrew V.
Venue: Nature Reviews Gastroenterology & Hepatology
Publisher: Springer Science and Business Media LLC
Published: 2019-02-04
Volume: 16
Issue: 4
Pages: 207-220
ISSN: 1759-5045 (ISSN-L)
1759-5053
DOI: 10.1038/s41575-019-0109-y
OpenAlex: W2913268845
Cited by: 892
References: 119
Citations by year: 2026: 69 · 2025: 87 · 2024: 168 · 2023: 142 · 2022: 135 · 2021: 157 · 2020: 104 · 2019: 28
FWCI: 10.11
Type: journal article
Language: en
Open access: green
eprints.gla.ac.uk
Licence: cc-by-sa
www.springer.com/tdm (tdm)
Locations: Nature Reviews Gastroenterology & Hepatology (publishedVersion)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
Funders: Pancreatic Cancer UK (FLF2015_04_GLASGOW)
Wellcome Trust (103721/Z/14/Z)
Cancer Research UK (23526, 17263)
Medical Research Council (MR/N005813/1)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords: pancreatic cancer, molecular subtypes, molecular taxonomy, molecular subtyping, therapeutic targeting, treatment response, histological classification
MeSH terms: Clinical Decision-Making, Genetic Markers, Humans, Pancreatic Neoplasms, Prognosis, Biomarkers, Tumor, Risk Assessment, Carcinoma, Pancreatic Ductal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular subtypes of pancreatic cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks